Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection [PDF]
New England Journal of Medicine, 2015 published_or_final_versio
Jordan Feld +2 more
exaly +2 more sources
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial [PDF]
The Lancet Gastroenterology and Hepatology, 2018 BACKGROUND Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID.
Jason Grebely +2 more
exaly +5 more sources
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort [PDF]
Scientific ReportsSimplified (“minimal monitoring”) pathways can expand access to direct-acting antivirals (DAAs) by reducing visit burden. In Japan, where hepatitis C virus (HCV) patients are among the oldest worldwide, whether DAA regimens can be delivered safely and ...
Goki Suda +25 more
doaj +2 more sources
Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study [PDF]
VirusesBackground: The advent of direct-acting antivirals (DAAs) has marked a significant milestone in the therapeutic landscape of hepatitis C, greatly improving treatment efficacy.
Jae Hyun Yoon +8 more
doaj +2 more sources
Hepatitis C Virus (HCV) Recurrence and Death After Viral Clearance in an HCV-Viremic Donor to HCV-Negative Kidney Recipient [PDF]
Kidney MedicineCurrent direct-acting antiviral (DAA) regimens have achieved nearly universal viral eradication in hepatitis C virus (HCV) nucleic acid test (NAT)-positive donor to HCV-negative recipient (HCV NAT+/–) transplantation.
Shengliang He +8 more
doaj +2 more sources
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [PDF]
New England Journal of Medicine, 2015 BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C ...
Graham R Foster +2 more
exaly +2 more sources
Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study [PDF]
The Korean Journal of Internal Medicine, 2023 Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior ...
Jeong Heo +24 more
doaj +1 more source
SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
Pakistan Armed Forces Medical Journal, 2021 Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study.
Arif Qayyum Khan +5 more
doaj +1 more source
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis [PDF]
Clinical and Molecular Hepatology, 2021 Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis.
Po-Yao Hsu +23 more
doaj +1 more source
Журнал инфектологии, 2023 Aim – to evaluate the effect of direct antiviral drugs (sofosbuvir and velpatasvir) on the formation of the metabolic syndrome in patients with chronic hepatitis C with a high risk of its development 2 years after treatment.Materials and methods.
A. F. Novikova +3 more
doaj +1 more source